A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®
A Randomized, Open-label Phase III Non-inferiority Trial to Compare Indicators of Efficacy for MVA-BN® Smallpox Vaccine to ACAM2000® in 18-42 Year Old Healthy Vaccinia-naïve Subjects
Sponsor: Bavarian Nordic
A PHASE3 clinical study on 18-42 Year Old Healthy Vaccinia-naïve Subjects, this trial is completed. The trial is conducted by Bavarian Nordic and has accumulated 11 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Jan 2020 — Jan 2021 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Aug 2019 — Jan 2020 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Aug 2019 [monthly]
Active Not Recruiting PHASE3
-
Aug 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Mar 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bavarian Nordic
- US Army Medical Research Institute of Infectious Diseases
For direct contact, visit the study record on ClinicalTrials.gov .